PANCREATIC CANCER DIAGNOSES AND MORTALITY RATES CLIMB FIVE-YEAR SURVIVAL RATE FOR ...
(MENAFN- PR Newswire) "While we've seen incremental progress in the treatment of pancreatic cancer, it's sobering to know ...
Eavesdropping on organs: Immune system controls blood sugar levels during periods of low energy
A study published in Science by the Champalimaud Foundation reveals a surprising new role for the immune system. During ...
GEN1 小时
Mass Migration of Immune Cells Found to Regulate Blood Glucose Levels
Findings suggest targeting neuro-immune pathway could lead to strategies for managing diabetes, obesity or some types of ...
American Cancer Society12 小时
Cancer Incidence Rate for Women Under 50 Rises Above Men's
Cancer incidence continues to rise for many common cancers—especially for women. The incidence rate for women younger than 50 ...
cweb16 小时
Exelixis’ Price Target Raised at Truist, Shares Rise 2 percent
Exelixis (NASDAQ:EXEL) shares rose more than 2% intra-day today after Truist Securities analysts increased their price target ...
Oppenheimer bullish on Exelixis stock as cabo sales and R&D progress impress
Oppenheimer has raised the price target for Exelixis (NASDAQ:EXEL) shares to $41.00 from the previous target of $38.00, while ...
precisionmedicineonline9 小时
JP Morgan Healthcare Conference, Day 3: iTeos, AbbVie, Lexeo Therapeutics, Grail
On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.